FORMULATION AND EVALUATION OF CIPROFLOXACIN NANOSUSPENSION FOR ORAL DRUG DELIVERY: A COMPREHENSIVE REVIEW

Karthick S.*, Hariharaputhraayyanar

ABSTRACT

Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic extensively used for the treatment of various bacterial infections. However, its therapeutic performance following oral administration is limited by physicochemical and biopharmaceutical challenges, including low aqueous solubility under certain physiological conditions, variable dissolution behavior, and restricted oral bioavailability. Nanotechnology-based drug delivery systems, particularly nanosuspensions, have emerged as a promising strategy to overcome these limitations by reducing particle size to the nanometer range, thereby increasing the surface area, dissolution rate, and saturation solubility of poorly soluble drug particles. Nanosuspensions are submicron colloidal dispersions of pure drug particles stabilized by suitable surfactants or polymers, offering improved stability, enhanced drug loading, and greater formulation flexibility compared with conventional dosage forms. This review provides a comprehensive overview of the formulation and evaluation of ciprofloxacin nanosuspensions intended for oral drug delivery. The article discusses the physicochemical characteristics of ciprofloxacin, the rationale for nanosuspension development, and commonly employed preparation techniques, including media milling, high-pressure homogenization, nanoprecipitation, and ultrasonication. The roles of stabilizers such as Poloxamer 188, polyvinylpyrrolidone (PVP K30), hydroxypropyl methylcellulose (HPMC), and Tween 80 in improving formulation stability are also highlighted. Furthermore, the review summarizes critical characterization and evaluation parameters, including particle size, polydispersity index, zeta potential, drug content, saturation solubility, dissolution behavior, and stability assessment. Recent advances in ciprofloxacin nanosuspension research demonstrate significant improvements in dissolution characteristics, bioavailability, and therapeutic efficacy compared with conventional formulations. Despite encouraging outcomes, challenges related to large-scale manufacturing, long-term stability, and regulatory approval remain important considerations for successful clinical translation. Overall, ciprofloxacin nanosuspensions represent a promising oral drug delivery approach with the potential to improve therapeutic outcomes and patient compliance. Future research should focus on scalable manufacturing processes, optimized stabilizer selection, and comprehensive in vivo investigations to facilitate commercial development.

Keywords: Ciprofloxacin, Nanosuspension, Oral Drug Delivery, Bioavailability, Solubility Enhancement, Formulation, Characterization, Nanotechnology.